The clinical findings, which evaluated iza-bren in patients previously treated with third-generation EGFR inhibitors, indicate that the 2.5 mg/kg D1D8 Q3W regimen offers an optimal balance of efficacy and a manageable safety profile. This data echoes consistent clinical outcomes previously observed in Chinese patient populations, confirming the drug's potential across diverse global cohorts.

SystImmune, in collaboration with Bristol Myers Squibb, is now leveraging these findings to advance the IZABRIGHT-Lung01 registrational study. As a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, iza-bren functions by blocking survival signals in cancer cells while simultaneously delivering a Topo1i payload to induce cytotoxic stress. Dr. Jonathan Cheng, Chief Medical Officer at SystImmune, noted that the increased efficacy observed at the 2.5 mg/kg level marks a vital milestone in the company’s development timeline for the therapy. Detailed results are scheduled for an oral presentation by Dr. Alexander Spira on September 14 at the WCLC congress.